In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018

This study evaluated the in vitro activity of cefepime-zidebactam in comparison with that of ceftazidime-avibactam and other comparators against clinically significant Gram-negative bacillus isolates. A total of 3,400 nonduplicate Gram-negative clinical isolates were collected from 45 medical centers across China in the CHINET Program in 2018, including Enterobacterales (n = 2,228), Pseudomonas aeruginosa (n = 657), and Acinetobacter baumannii (n = 515). The activities of cefepime-zidebactam and 20 comparators were determined by broth microdilution as recommended by the Clinical and Laboratory Standards Institute. Cefepime-zidebactam demonstrated potent activity against almost all Enterobacterales (MIC50/90, 0.125/ 1 mg/liter) and good activity against P. aeruginosa (MIC50/90, 2/8 mg/liter). Among the 373 carbapenem-resistant Enterobacteriaceae isolates, 57.3% (213/373) and 15.3% (57/373) were positive for bla(KPC-2) and bla(NDM), respectively. Cefepime-zidebactam showed a MIC of <= 2 mg/liter for 92.0% (196/213) of bla(KPC-2) producers and 79.7%(47/59) of bla(NDM) producers. Ceftazidime-avibactam showed good in vitro activity against Enterobacterales (MIC50/90, 0.25/2 mg/liter; 94.0% susceptible) and P. aeruginosa (MIC50/90, 4/16 mg/liter; 86.9% susceptible). Ceftazidime-avibactam was active against 9.1% of carbapenem-resistant Escherichia coli isolates (63.6% were bla(NDM) producers) and 84.6% of Klebsiella pneumoniae isolates (74.3% were bla(KPC) producers). Most (90.1%) bla(KPC-2) producers were susceptible to ceftazidime-avibactam. Cefepime-zidebactam demonstrated limited activity (MIC50/90, 16/32 mg/liter) against the 515 A. baumannii isolates (79.2% were carbapenem resistant), and ceftazidime-avibactam was less active (MIC50/90, 64/>64 mg/liter). Cefepime-zidebactam was highly active against clinical isolates of Enterobacterales and P. aeruginosa, including bla(KPC-2)-positive Enterobacterales and bla(NDM)-positive Enterobacterales and carbapenem-resistant P. aeruginosa. And ceftazidime-avibactam was highly active against bla(KPC-2)-positive Enterobacterales and carbapenem-resistant P. aeruginosa.

Automated summary

The study found that cefepime-zidebactam exhibited potent activity against almost all Enterobacterales and good activity against P. aeruginosa, while ceftazidime-avibactam showed good in vitro activity against Enterobacterales and P. aeruginosa but less activity against Acinetobacter baumannii. Most of the carbapenem-resistant Enterobacteriaceae isolates were susceptible to cefepime-zidebactam and ceftazidime-avibactam showed good activity against bla(KPC-2)-positive Enterobacterales and carbapenem-resistant P. aeruginosa.